16+
Major trials tracked
Two PD-1 checkpoint inhibitors in oncology
Nivolumab vs pembrolizumab: trial pipelines compared
A side-by-side view of the nivolumab and pembrolizumab clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for nivolumab and 16+ for pembrolizumab. Add up to three more drugs to widen the comparison.
nivolumab (16) vs pembrolizumab (16)25 active2013–2034
nivolumabpembrolizumab
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
'33
nivolumab
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)P2
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerP2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)P2
TAPURP2
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersP4
CheckMate 908P2
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaP3
CaboPointP2
TONIC-2P2
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaP2
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaP3
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)P2
Nivo40-AVD for Advanced Classic Hodgkin LymphomaP2
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II TrialP2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerP2
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialP2
pembrolizumab
Pembrolizumab and Epacadostat in Patients With Thymic CarcinomaP2
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerP2
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)P3
TACTI-002P2
LEAP-001P3
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCP2
SEAMARKP2
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckP2
Pembro-SRTP2
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaP3
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerP3
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.P2
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)P3
Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II TrialP2
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaP2
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerP3
Upcoming readouts
14 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
nivolumab (Opdivo)Immuno-oncology checkpoint inhibitors
2
Phase 3 trials
5
Actively recruiting
Nov 2028
Next phase 3 readout
pembrolizumab (Keytruda)Immuno-oncology checkpoint inhibitors
16+
Major trials tracked
6
Phase 3 trials
4
Actively recruiting
Dec 2026
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across nivolumab and pembrolizumab, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track nivolumab and pembrolizumab with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the nivolumab and pembrolizumab clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for nivolumab and 16+ for pembrolizumab. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.
